Baclofen, Diltiazem
PreclinicalSmall molecule
Baclofen, Diltiazem is one of 3 small molecule programs targeting Hyperalgesia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Hyperalgesia
#DrugCompanyPhaseTrials
1Alfenta
Jazz PharmaceuticalsPreclinical
Acupan
YYonsei University
Preclinical
Baclofen, Diltiazem
CChinese University of Hong Kong
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hyperalgesia1 trial
Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?
Terminated·—·N/A·NCT00164801·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Baclofen, Diltiazem. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CChinese University of Hong Kong